Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Secondary

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Secondary cohort.

Asset / SponsorPhaseRating
Eloxatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Capecitabine
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
SACUBITRIL VALSARTAN
Silesian Centre for Heart Diseases
Phase 4BB
Irinotecan
Ludwig-Maximilians - University of Munich
Phase 2BB
Everolimus
Gynaecologisch Oncologisch Centrum Zuid
Phase 2/3B

View all 21 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →